Prediction value of serum HBV large surface protein in different phases of HBV infection and virological response of chronic hepatitis B patients
Prediction value of serum HBV large surface protein in different phases of HBV infection and virological response of chronic hepatitis B patients
复制标题
血清HBV大表面蛋白对HBV感染不同时期及慢性乙型肝炎患者病毒学应答的预测价值
DOI：
10.1016/j.cca.2018.02.015
复制
发表时间：
2018-06-01
影响因子：
5
通讯作者：
Ou, Qishui
中科院分区：
文献类型：
--
作者：
Liu, Can;Wu, Wennan;Ou, Qishui
背景：血清HBV大表面蛋白（HBV-LP）是一种与HBV DNA水平密切相关的包膜蛋白。为探讨血清HBV-LP水平对慢性B肝炎（CHB）患者HBV感染不同阶段及抗病毒治疗的预测价值，采用回顾性研究方法，对1677例不同阶段的CHB患者及356例健康对照者2033例进行分析。采用ELISA法检测HBV LP，CMIA法检测HBV血清标志物，qRT-PCR法检测HBV DNA。85例接受PegIFN α或ETV治疗的CHB患者分为病毒学应答（VR）和部分病毒学应答（PVR）。结果：2033名受试者的HBV-LP水平依次为：HBeAg阳性肝炎> HBeAg阳性感染> HBeAg阴性肝炎> HBeAg阴性感染>健康对照。HBV DNA > 1.0E + 06 IU/ml者均为HBV LP阳性。当HBsAg < 0.05 IU/ml或> 1000 IU/ml时，HBV-LP < 1.0 S/CO者HBV-DNA均为阴性，当HBsAg在0.05 ~ 1000 IU/ml时，HBeAg阳性者HBV-LP > 4.0 S/CO者HBV-LP与HBVDNA的符合率为100%，HBeAg阴性者HBV-LP > 2.0 S/CO者HBV-LP与HBVDNA的符合率为100%。在抗病毒治疗期间，VR患者的基线HBV-LP低于PVR患者。以基线HBV-LP预测VR的最佳截断点分别为32.4和28.6 S/CO，HBeAg阳性和HBeAg阴性的肝炎患者。结论：HBV-LP可能是区分HBV感染不同阶段的有用指标。此外，基线HBV-LP水平可用于预测CHB患者的VR。
Background: Serum HBV large surface protein (HBV-LP) is an envelope protein that has a close relationship with HBV DNA level. This study is to explore the prediction value of HBV-LP in different phase of HBV infection and during antiviral therapy in chronic hepatitis B (CHB) patients.Methods: A retrospective study was conducted in 2033 individuals, which included 1677 HBV infected patients in different phases and 356 healthy controls. HBV-LP, HBV serum markers and HBV DNA were detected by ELISA, CMIA and qRT-PCR, respectively. 85 CHB patients receiving PegIFN alpha or ETV were divided into virological response (VR) and partial virological response (PVR). The dynamic changes of HBV DNA and HBV-LP were observed.Results: The level of HBV-LP in 2033 individuals was shown as: HBeAg-positive hepatitis > HBeAg-positive infection > HBeAg-negative hepatitis > HBeAg-negative infection > healthy controls. HBV-LP was positive in all patients whose HBV DNA > 1.0E + 06 IU/ml. When HBsAg was < 0.05 IU/ml or > 1000 IU/ml, HBV DNAs were all negative if HBV-LP < 1.0 S/CO. When HBsAg was between 0.05 IU/ml and 1000 IU/ml, the consistency of HBV-LP with HBV DNA was 100% in case of HBV-LP > 4.0 S/CO in HBeAg-positive patients and HBV-LP > 2.0 S/CO in HBeAg-negative ones. During antiviral therapy, baseline HBV-LP was lower in VR patients than that in PVR patients. The optimal cut-off points to predict VR by baseline HBV-LP were 32.4 and 28.6 S/CO for HBeAg-positive and HBeAg-negative hepatitis patients, respectively.Conclusions: HBV-LP may be a useful marker for distinguishing the different phases of HBV infection. Moreover, baseline HBV-LP level can be used for predicting VR of CHB patients.